Edgar Filing: Naydenov Jordan G

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Naydenov Jordan G

2. Issuer Name and Ticker or Trading Symbol
CytoDyn Inc. [CYDY]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

1111 MAIN STREET, SUITE 660

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2018

(Street)

VANCOUVER, WA 98660

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/16/2018		A		5,304,490	A	⁽¹⁾ ⁽²⁾	5,304,490	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Options (right to buy)

$ 0.66

11/16/2018

50,000

06/01/2015

06/01/2019

Common Stock

50,000

⁽¹⁾ ⁽²⁾

50,000

Stock Options (right to buy)

$ 2

11/16/2018

50,000

08/08/2012

08/08/2021

Common Stock

50,000

⁽¹⁾ ⁽²⁾

50,000

Stock Options (right to buy)

$ 1.55

11/16/2018

25,000

06/01/2013

06/01/2022

Common Stock

25,000

⁽¹⁾ ⁽²⁾

25,000

Stock Options (right to buy)

$ 0.975

11/16/2018

50,000

09/01/2016

06/01/2025

Common Stock

50,000

⁽¹⁾ ⁽²⁾

50,000

Stock Options (right to buy)

$ 1.09

11/16/2018

50,000

06/01/2017

06/01/2026

Common Stock

50,000

⁽¹⁾ ⁽²⁾

50,000

Stock Options (right to buy)

$ 0.57

11/16/2018

75,000

09/01/2018

06/01/2027

Common Stock

75,000

⁽¹⁾ ⁽²⁾

75,000

Stock Options (right to buy)

$ 0.56

11/16/2018

96,397

02/07/2018

02/07/2028

Common Stock

96,397

⁽¹⁾ ⁽²⁾

96,397

Stock Options (right to buy)

$ 0.8

11/16/2018

50,000

02/15/2018

02/15/2023

Common Stock

50,000

⁽¹⁾ ⁽²⁾

50,000

Stock Options (right to buy)

$ 0.49

11/16/2018

100,000

⁽³⁾

06/08/2028

Common Stock

100,000

⁽¹⁾ ⁽²⁾

100,000

Warrants (right to buy)

$ 0.75

11/16/2018

133,334

01/31/2018

01/31/2023

Common Stock

133,334

⁽¹⁾ ⁽²⁾

133,334

Warrants (right to buy)

$ 0.75

11/16/2018

66,666

01/31/2018

07/26/2022

Common Stock

66,666

⁽¹⁾ ⁽²⁾

66,666

Warrants (right to buy)

$ 1.35

11/16/2018

250,000

05/10/2016

05/10/2021

Common Stock

250,000

⁽¹⁾ ⁽²⁾

250,000

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Naydenov Jordan G 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660	X

Signatures

/s/ Michael D. Mulholland, as attorney-in-fact		11/16/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.
(2)	In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance).
(3)	The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.